Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
115 studies found for:    myeloma and lenalidomide | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone
2 Recruiting Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Condition: Multiple Myeloma
Intervention: Drug: Revlimid (lenalidomide)
3 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
4 Recruiting Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Palbociclib;   Drug: Dexamethasone;   Drug: Lenalidomide
5 Recruiting Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Sonidegib
6 Recruiting Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
7 Recruiting Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Carfilzomib;   Drug: Dexamethasone
8 Recruiting Treatment Optimization in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Placebo
9 Recruiting Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
10 Recruiting Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Conditions: Multiple Myeloma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Romidepsin;   Drug: Lenalidomide
11 Recruiting A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
12 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
13 Recruiting Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Nelfinavir;   Drug: Lenalidomide;   Drug: Dexamethasone
14 Recruiting Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
Conditions: Renal Failure;   Multiple Myeloma
Intervention: Drug: Lenalidomide and Dexamethasone
15 Recruiting Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, Dexamethasone;   Drug: Lenalidomide, Dexamethasone, PBSCT
16 Recruiting Lenalidomide Maintenance in Plasma Cell Myeloma
Condition: Plasma Cell Myeloma
Intervention: Drug: Lenalidomide
17 Recruiting Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Other: autologous PBMC reconstitution;   Other: ASCT
18 Recruiting Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Condition: Multiple Myeloma (MM)
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Lenalidomide
19 Not yet recruiting Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone
20 Not yet recruiting A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
Condition: Smoldering Multiple Myeloma
Interventions: Drug: Hiltonol;   Drug: Durvalumab;   Drug: Lenalidomide;   Biological: PVX-410

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.